Clal Insurance Enterprises Holdings Ltd Purchases 13,200 Shares of Eli Lilly and Company (NYSE:LLY)

Clal Insurance Enterprises Holdings Ltd grew its position in Eli Lilly and Company (NYSE:LLY) by 18.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 84,800 shares of the company’s stock after buying an additional 13,200 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Eli Lilly and Company were worth $75,128,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Bellevue Group AG boosted its position in shares of Eli Lilly and Company by 3.1% in the 1st quarter. Bellevue Group AG now owns 57,965 shares of the company’s stock worth $45,094,000 after purchasing an additional 1,753 shares in the last quarter. Ceeto Capital Group LLC increased its holdings in shares of Eli Lilly and Company by 4.9% during the first quarter. Ceeto Capital Group LLC now owns 2,130 shares of the company’s stock valued at $1,657,000 after acquiring an additional 100 shares in the last quarter. Morse Asset Management Inc increased its holdings in shares of Eli Lilly and Company by 6.7% during the first quarter. Morse Asset Management Inc now owns 11,139 shares of the company’s stock valued at $8,666,000 after acquiring an additional 701 shares in the last quarter. Beaird Harris Wealth Management LLC boosted its stake in Eli Lilly and Company by 10.6% in the 1st quarter. Beaird Harris Wealth Management LLC now owns 501 shares of the company’s stock worth $390,000 after purchasing an additional 48 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC increased its stake in Eli Lilly and Company by 6.7% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 4,408 shares of the company’s stock valued at $3,429,000 after purchasing an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Trading Down 0.3 %

LLY opened at $748.01 on Friday. The business has a fifty day moving average price of $865.01 and a 200 day moving average price of $869.01. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The stock has a market capitalization of $710.10 billion, a price-to-earnings ratio of 80.87, a PEG ratio of 2.84 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The firm’s revenue was up 20.4% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.